New combo therapy shows promise for advanced melanoma

NCT ID NCT03815058

Completed Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding a personalized cancer vaccine (RO7198457) to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for people with advanced melanoma that hasn't been treated before. The trial involved 131 participants and measured how long the cancer stayed under control. The goal is to improve treatment options for this serious skin cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MELANOMA

Contacts and locations

Locations

Alfred Hospital

Melbourne, Victoria, 3181, Australia
Antwerp University Hospital

Edegem, 2650, Belgium
Atlanta Cancer Care

Alpharetta, Georgia, 30005, United States
Barts and The London

London, EC1M 6BQ, United Kingdom
Cancer Specialists

Jacksonville, Florida, 32256, United States
Case Western Research University

Cleveland, Ohio, 44106-5067, United States
City of Hope Comprehensive Cancer Center

Duarte, California, 91010, United States
Clinica Universidad de Navarra

Pamplona, Navarre, 31008, Spain
Elbe Kliniken Stade-Buxtehude GmbH

Buxtehude, 21614, Germany
Fachklinik Hornheide

Münster, 48157, Germany
Hospital Clinic de Barcelona

Barcelona, 08036, Spain
Hospital General Universitario Gregorio Marañon

Madrid, 28007, Spain
Hospital Universitario La Paz

Madrid, 280146, Spain
Hospital Universitario Virgen Macarena

Seville, 41009, Spain
Huntsman Cancer Institute

Salt Lake City, Utah, 84112, United States
Instituto Oncológico Dr. Rosell

Barcelona, 08028, Spain
Intermountain Surgical Oncology

Murray, Utah, 84107, United States
Liverpool Hospital

Liverpool, New South Wales, 2170, Australia
Massachusetts General Hospital.

Boston, Massachusetts, 02114, United States
Med. Fakultat Mannheim der Universitat Heidelberg

Mannheim, 68167, Germany
Moffitt McKinley Outpatient Center

Tampa, Florida, 33612, United States
Northwestern University

Chicago, Illinois, 60611, United States
Oregon Health and Science University

Portland, Oregon, 97239, United States
Peter MacCallum Cancer Centre

Melbourne, Victoria, 3000, Australia
Sarah Cannon Research Institute / Tennessee Oncology

Nashville, Tennessee, 37203, United States
Seattle Cancer Care Alliance

Seattle, Washington, 98109, United States
St. John of God - Subiaco Hospital

Subiaco, Western Australia, 6008, Australia
The Queen Elizabeth Hospital

Woodville South, South Australia, 5011, Australia
UCSF Comprehensive Cancer Ctr

San Francisco, California, 94115, United States
Uni Schleswig-Holstein

Lübeck, 23562, Germany
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR, Hautklinik und Poliklinik

Mainz, 55131, Germany
Universitatsklinikum Eppendorf

Hamburg, 20246, Germany
University of California San Diego Moores Cancer Center

La Jolla, California, 92037, United States
University of Colorado

Denver, Colorado, 80262, United States
University of Virginia

Charlottesville, Virginia, 22906, United States
Universitätshautk. Tübingen

Tübingen, 72076, Germany
Universitätsklinikum Heidelberg

Heidelberg, 69120, Germany
Universitätsklinikum Koeln

Cologne, 50937, Germany
Vall d?Hebron Institute of Oncology (VHIO), Barcelona

Barcelona, 08035, Spain
Washington University

St Louis, Missouri, 63110, United States
ZAS Sint Augustinus Wilrijk

Wilrijk, 2610, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.